Neuberger Berman Group
CLVS

Neuberger Berman Group’s Clovis Oncology, Inc. CLVS Stock Holding History

Neuberger Berman Group’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-16,000
Closed -$397K – 1607
2019
Q1 		$397K Buy
+16,000
New +$401K ﹤0.01% 1304
2018
Q3 		– Sell
-23,406
Closed -$1.06M – 1727
2018
Q2 		$1.06M Buy
+23,406
New +$1.14M ﹤0.01% 1214
2017
Q4 		– Sell
-11,000
Closed -$906K – 1836
2017
Q3 		$906K Buy
+11,000
New +$872K ﹤0.01% 1177
2015
Q4 		– Sell
-160,959
Closed -$14.8M – 1586
2015
Q3 		$14.8M Buy
160,959
+152,170
+1,731% +$13.2M 0.02% 707
2015
Q2 		$772K Buy
+8,789
New +$752K ﹤0.01% 1247
2013
Q4 		– Sell
-4,800
Closed -$292K – 1676
2013
Q3 		$292K Buy
4,800
+1,687
+54% +$120K ﹤0.01% 1410
2013
Q2 		$209K Buy
+3,113
New +$140K ﹤0.01% 1485

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return